Flamma acquired the Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area in 2019. The 40,000 sq. ft. facility is in close proximity to Boston/Cambridge (1.5 h flight) as well as the greater New York/New Jersey area (1.5 h drive).
Affectionately being dubbed “Flamma-delphia” for now, this extremely well built lab and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, 1 cGMP HPAPI kilo lab suite with isolators that have been classified 3b(Roche) or band 4 (Safebridge), 22 fume hoods, an analytical development lab as well as a QC lab, and additional space for future expansion for any necessary analytical, chemistry, and/or warehouse needs. Also, the site previously handled controlled drug substances (Schedule II to IV) and Flamma looks forward to reactivating the necessary licenses.
This site will be to be fully dedicated to the development and production of APIs ranging from pre-clinical/clinical phases (1 to 3) and up to commercial phase with the scale being dependent on the forecasted quantities. Flamma plans to grow the site to 60 employees by 2023 and looks forward to attracting talented personnel that reside in the Philly area.
If you would like to have a site visit to see the value that Flamma can bring to your company , please contact Kenneth Drew, Ph.D., Senior Director of North America Sales and Business Development via the contact page by using the drop down menu for “Direct contact to North America Representative”